High-Dose Niacin Shows Promise Against Aggressive Brain Cancer

University of Calgary researchers are testing high-dose vitamin B3 (niacin) alongside standard glioblastoma treatment to revive immune cells and attack tumors. In an early Phase I/II trial, 24 patients showed a six-month progression-free survival of 82% — about 28% better than earlier studies — suggesting niacin could boost immune response against this deadly brain cancer, though safety at high doses remains a key consideration as the study continues toward 48 participants by late 2026/early 2027.